Sotorasib Patent Expiration
Sotorasib is Used for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. It was first introduced by Amgen Inc
Sotorasib Patents
Given below is the list of patents protecting Sotorasib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lumakras | US11426404 | Dosing of KRAS inhibitor for treatment of cancers | Sep 15, 2040 | Amgen Inc |
| Lumakras | US11236091 | Solid state forms | May 20, 2040 | Amgen Inc |
| Lumakras | US11827635 | Solid state forms | May 20, 2040 | Amgen Inc |
| Lumakras | US12398133 | Solid State Forms | May 20, 2040 | Amgen Inc |
| Lumakras | US12280056 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | Nov 18, 2039 | Amgen Inc |
| Lumakras | US10519146 | KRAS G12C inhibitors and methods of using the same | May 21, 2038 | Amgen Inc |
Sotorasib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sotorasib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
